The combination of regorafenib, nivolumab and SCRT shows promising efficacy as neoadjuvant therapy for locally advanced RC

Trifluridine/tipiracil followed by regorafenib can be an effective treatment sequence in pretreated mCRC

Durvalumab, gemcitabine and cisplatin continue to show clinically meaningful long-term survival in biliary tract cancer patients

Biomarkers, predictive and prognostic factors of resistance to immunotherapy

Research highlights in gastrointestinal tumours

Research highlights in lung cancer

Treatment of anxiety and depression in cancer patients using intergtaive medicine

Updates from ASCO 2024 in gastrointestinal tumours

Research highlights in breast cancer

GIST tumours and soft tissue sarcomas

Hormonal receptor positive breast cancer adjuvant and metastatic indications

Antibody drug conjugates coming to primetime and new agents for breast cancer